Quarterly ResultMay 8, 2026, 04:22 PM
Regencell Bioscience H1 2026 Net Loss Widens to $5.32M; Faces Lawsuit
AI Summary
Regencell Bioscience Holdings Ltd reported a significant increase in net loss for the first half of fiscal year 2026, reaching $5.32 million, up 187% from the prior year. This was primarily driven by a 170% surge in total operating expenses, largely due to increased share-based compensation and professional fees related to investigation matters. The company also disclosed a going concern warning due to recurring losses and negative cash flows, and is facing a putative class action complaint filed by a shareholder regarding stock volatility.
Key Highlights
- Net loss increased 187% to $5.32 million for the six months ended December 31, 2025.
- Loss per share was $(1.08) for H1 2026, up from $(0.37) in H1 2025.
- Total operating expenses surged 170% to $5.34 million for H1 2026.
- General and administrative expenses rose 236% to $4.92 million, driven by share-based compensation and legal fees.
- Company issued a going concern warning due to recurring losses and negative cash flows.
- Regencell Bioscience is facing a class action lawsuit regarding stock volatility.
- Total assets decreased to $3.01 million as of December 31, 2025, from $5.76 million.
- Net cash used in operating activities was $2.59 million for H1 2026.